Advanced Micro Devices
AMD
ASML Holding
ASML
Meta Platforms
META
Cisco
CSCO
Intel
INTC
US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 2.010
- +0.020+1.01%
Close Dec 27 16:00 ET
- 1.960
- -0.050-2.49%
Post 20:01 ET
37.90MMarket Cap-2.14P/E (TTM)
2.010High1.900Low120.84KVolume2.000Open1.990Pre Close239.73KTurnover1.02%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High2.32P/B23.76MFloat Cap0.46052wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM5.53%Amplitude0.420Historical Low1.983Avg Price1Lot Size
Chemomab Therapeutics News
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Cuts Target Price to $11
Chemomab Therapeutics Analyst Ratings
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Chemomab Therapeutics (CMMB) Gets a Buy From Oppenheimer
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $9
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $13
Chemomab Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)
Chemomab Therapeutics Analyst Ratings
Chemomab Therapeutics Analyst Ratings
Roth MKM Reinstates Buy on Chemomab Therapeutics, Maintains $7 Price Target
Chemomab Therapeutics Analyst Ratings
Oppenheimer Reaffirms Their Hold Rating on Chemomab Therapeutics (CMMB)
Roth MKM Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $7
Chemomab Therapeutics Analyst Ratings
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.